About
Cyclic peptide analog
Areas of Focus
Categories
Gene Therapy, RNA & Peptide TherapyAustralia
Clinical Trials (31)
View allTotal Trials
31
As Lead Sponsor
28
As Collaborator
3
Total Enrollment
5,200
By Phase
PHASE2/PHASE3: 2PHASE3: 10PHASE2: 9NA: 1PHASE1/PHASE2: 2PHASE1: 4
By Status
COMPLETED: 17ACTIVE_NOT_RECRUITING: 4NOT_YET_RECRUITING: 3RECRUITING: 3TERMINATED: 2UNKNOWN: 1AVAILABLE: 1
Clinical Trials Pipeline30 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT07213960Lead Sponsor
A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis
PHASE2/PHASE3Not yet recruiting
270 participants
Started: Dec 31, 2025 · Completed: Dec 31, 2029
NCT07214740Lead Sponsor
Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe
PHASE3Not yet recruiting
36 participants
Started: Oct 31, 2025 · Completed: Jan 31, 2026
NCT07020832Lead Sponsor
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
PHASE3Not yet recruiting
320 participants
Started: Sep 30, 2025 · Completed: Aug 31, 2028
NCT07215390Lead Sponsor
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
PHASE2Recruiting
240 participants
Started: Jun 23, 2025 · Completed: Nov 30, 2027
NCT06161584Lead Sponsor
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
N/ARecruiting
300 participants
Started: Sep 28, 2023 · Completed: Jun 30, 2028
Locations (1)
Headquarters
Hawthorn East, Australia
Map
Loading map...